Standards and guidelines for CFTR mutation testing

Carolyn (Sue) Richards, Linda A. Bradley, Jean Amos, Bernice Allitto, Wayne W. Grody, Anne Maddalena, Matthew J. McGinnis, Thomas W. Prior, Bradley W. Popovich, Michael S. Watson

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

One mission of the ACMG Laboratory Quality Assurance (QA) Committee is to develop standards and guidelines for clinical genetics laboratories, including cytogenetics, biochemical, and molecular genetics specialties. This document was developed under the auspices of the Molecular Subcommittee of the Laboratory QA Committee by the Cystic Fibrosis (CF) Working Group. It was placed on the "fast track" to address the preanalytical, analytical, and postanalytical quality assurance practices of laboratories currently providing testing for CF. Due to the anticipated impact of the ACMG recommendation statement endorsing carrier testing of reproductive couples, it was viewed that CF testing would increase in volume and that the number of laboratories offering CF testing would also likely increase. Therefore, this document was drafted with the premise of providing useful information gained by experienced laboratory directors who have provided such testing for many years. In many instances, "tips" are given. However, these guidelines are not to be interpreted as restrictive or the only approach but to provide a helpful guide. Certainly, appropriately trained and credentialed laboratory directors have flexibility to utilize various testing platforms and design testing strategies with considerable latitude. We felt that it was essential to include technique-specific guidelines of several current technologies commonly used in laboratories providing CF testing, since three of the four technologies discussed are available commercially and are widely utilized. We take the view that these technologies will change, and thus this document will change with future review.

Original languageEnglish (US)
Pages (from-to)379-391
Number of pages13
JournalGenetics in Medicine
Volume4
Issue number5
DOIs
StatePublished - Sep 2002
Externally publishedYes

Fingerprint

Guidelines
Mutation
Cystic Fibrosis
Technology
Molecular Biology
Cytogenetics

Keywords

  • CFTR
  • Cystic fibrosis
  • Genetic testing
  • Medical genetics
  • Molecular diagnostics

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Richards, C. S., Bradley, L. A., Amos, J., Allitto, B., Grody, W. W., Maddalena, A., ... Watson, M. S. (2002). Standards and guidelines for CFTR mutation testing. Genetics in Medicine, 4(5), 379-391. https://doi.org/10.1097/00125817-200209000-00010

Standards and guidelines for CFTR mutation testing. / Richards, Carolyn (Sue); Bradley, Linda A.; Amos, Jean; Allitto, Bernice; Grody, Wayne W.; Maddalena, Anne; McGinnis, Matthew J.; Prior, Thomas W.; Popovich, Bradley W.; Watson, Michael S.

In: Genetics in Medicine, Vol. 4, No. 5, 09.2002, p. 379-391.

Research output: Contribution to journalArticle

Richards, CS, Bradley, LA, Amos, J, Allitto, B, Grody, WW, Maddalena, A, McGinnis, MJ, Prior, TW, Popovich, BW & Watson, MS 2002, 'Standards and guidelines for CFTR mutation testing', Genetics in Medicine, vol. 4, no. 5, pp. 379-391. https://doi.org/10.1097/00125817-200209000-00010
Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A et al. Standards and guidelines for CFTR mutation testing. Genetics in Medicine. 2002 Sep;4(5):379-391. https://doi.org/10.1097/00125817-200209000-00010
Richards, Carolyn (Sue) ; Bradley, Linda A. ; Amos, Jean ; Allitto, Bernice ; Grody, Wayne W. ; Maddalena, Anne ; McGinnis, Matthew J. ; Prior, Thomas W. ; Popovich, Bradley W. ; Watson, Michael S. / Standards and guidelines for CFTR mutation testing. In: Genetics in Medicine. 2002 ; Vol. 4, No. 5. pp. 379-391.
@article{42af1d58c4994f3590d38cc2650b50fe,
title = "Standards and guidelines for CFTR mutation testing",
abstract = "One mission of the ACMG Laboratory Quality Assurance (QA) Committee is to develop standards and guidelines for clinical genetics laboratories, including cytogenetics, biochemical, and molecular genetics specialties. This document was developed under the auspices of the Molecular Subcommittee of the Laboratory QA Committee by the Cystic Fibrosis (CF) Working Group. It was placed on the {"}fast track{"} to address the preanalytical, analytical, and postanalytical quality assurance practices of laboratories currently providing testing for CF. Due to the anticipated impact of the ACMG recommendation statement endorsing carrier testing of reproductive couples, it was viewed that CF testing would increase in volume and that the number of laboratories offering CF testing would also likely increase. Therefore, this document was drafted with the premise of providing useful information gained by experienced laboratory directors who have provided such testing for many years. In many instances, {"}tips{"} are given. However, these guidelines are not to be interpreted as restrictive or the only approach but to provide a helpful guide. Certainly, appropriately trained and credentialed laboratory directors have flexibility to utilize various testing platforms and design testing strategies with considerable latitude. We felt that it was essential to include technique-specific guidelines of several current technologies commonly used in laboratories providing CF testing, since three of the four technologies discussed are available commercially and are widely utilized. We take the view that these technologies will change, and thus this document will change with future review.",
keywords = "CFTR, Cystic fibrosis, Genetic testing, Medical genetics, Molecular diagnostics",
author = "Richards, {Carolyn (Sue)} and Bradley, {Linda A.} and Jean Amos and Bernice Allitto and Grody, {Wayne W.} and Anne Maddalena and McGinnis, {Matthew J.} and Prior, {Thomas W.} and Popovich, {Bradley W.} and Watson, {Michael S.}",
year = "2002",
month = "9",
doi = "10.1097/00125817-200209000-00010",
language = "English (US)",
volume = "4",
pages = "379--391",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Standards and guidelines for CFTR mutation testing

AU - Richards, Carolyn (Sue)

AU - Bradley, Linda A.

AU - Amos, Jean

AU - Allitto, Bernice

AU - Grody, Wayne W.

AU - Maddalena, Anne

AU - McGinnis, Matthew J.

AU - Prior, Thomas W.

AU - Popovich, Bradley W.

AU - Watson, Michael S.

PY - 2002/9

Y1 - 2002/9

N2 - One mission of the ACMG Laboratory Quality Assurance (QA) Committee is to develop standards and guidelines for clinical genetics laboratories, including cytogenetics, biochemical, and molecular genetics specialties. This document was developed under the auspices of the Molecular Subcommittee of the Laboratory QA Committee by the Cystic Fibrosis (CF) Working Group. It was placed on the "fast track" to address the preanalytical, analytical, and postanalytical quality assurance practices of laboratories currently providing testing for CF. Due to the anticipated impact of the ACMG recommendation statement endorsing carrier testing of reproductive couples, it was viewed that CF testing would increase in volume and that the number of laboratories offering CF testing would also likely increase. Therefore, this document was drafted with the premise of providing useful information gained by experienced laboratory directors who have provided such testing for many years. In many instances, "tips" are given. However, these guidelines are not to be interpreted as restrictive or the only approach but to provide a helpful guide. Certainly, appropriately trained and credentialed laboratory directors have flexibility to utilize various testing platforms and design testing strategies with considerable latitude. We felt that it was essential to include technique-specific guidelines of several current technologies commonly used in laboratories providing CF testing, since three of the four technologies discussed are available commercially and are widely utilized. We take the view that these technologies will change, and thus this document will change with future review.

AB - One mission of the ACMG Laboratory Quality Assurance (QA) Committee is to develop standards and guidelines for clinical genetics laboratories, including cytogenetics, biochemical, and molecular genetics specialties. This document was developed under the auspices of the Molecular Subcommittee of the Laboratory QA Committee by the Cystic Fibrosis (CF) Working Group. It was placed on the "fast track" to address the preanalytical, analytical, and postanalytical quality assurance practices of laboratories currently providing testing for CF. Due to the anticipated impact of the ACMG recommendation statement endorsing carrier testing of reproductive couples, it was viewed that CF testing would increase in volume and that the number of laboratories offering CF testing would also likely increase. Therefore, this document was drafted with the premise of providing useful information gained by experienced laboratory directors who have provided such testing for many years. In many instances, "tips" are given. However, these guidelines are not to be interpreted as restrictive or the only approach but to provide a helpful guide. Certainly, appropriately trained and credentialed laboratory directors have flexibility to utilize various testing platforms and design testing strategies with considerable latitude. We felt that it was essential to include technique-specific guidelines of several current technologies commonly used in laboratories providing CF testing, since three of the four technologies discussed are available commercially and are widely utilized. We take the view that these technologies will change, and thus this document will change with future review.

KW - CFTR

KW - Cystic fibrosis

KW - Genetic testing

KW - Medical genetics

KW - Molecular diagnostics

UR - http://www.scopus.com/inward/record.url?scp=0036727811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036727811&partnerID=8YFLogxK

U2 - 10.1097/00125817-200209000-00010

DO - 10.1097/00125817-200209000-00010

M3 - Article

C2 - 12394352

AN - SCOPUS:0036727811

VL - 4

SP - 379

EP - 391

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 5

ER -